Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung

Ikehara, Mizuki; Oshita, Fumihiro; Kameda, Yoichi; Ito, Hiroyuki; Ohgane, Naoki; Suzuki, Rie; Saito, Haruhiro; Yamada, Katsushi; Noda, Kazumasa; Mitsuda, Aki

doi:10.3892/or.9.4.835

Cited by 39 publications

(43 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In NSCLC and adenocarcinoma of the lung, survivin expression has been related to poor patient survival and tumor invasion (37,38). In our study, survivin overexpression was not correlated with any patient characteristics of adverse disease.…”

Section: Discussionmentioning

confidence: 55%

Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients

Vischioni

Oudejans²,

Vos³

et al. 2006

Molecular Cancer Therapeutics

119

View full text Add to dashboard Cite

The serine/threonine protein kinase aurora B, a key regulator of mitosis, is emerging as a novel drug target for cancer treatment. Aurora B overexpression has been previously documented by immunohistochemistry in several types of human tumors. We assessed aurora B expression in a series of 160 non -small cell lung cancer (NSCLC) samples (60% stage I, 21% stage II, 11% stage III, and 8% stage IV). In addition, we determined the expression of survivin and p16, two molecules also involved in cell cycle control. Aurora B was expressed selectively in tumor cells compared with normal epithelium. Aurora B expression was significantly correlated with expression of survivin in the nucleus (P < 0.0001), but not with expression of p16 (P = 0.134). High aurora B expression levels were significantly associated with older age (P = 0.012), male sex (P = 0.013), squamous cell carcinoma histology (P = 0.001), poor tumor differentiation grade (P = 0.007), and lymph node invasion (P = 0.037), in the subset of radically resected patients in our series. In addition, aurora B expression predicted shorter survival for the patients with adenocarcinoma histology, at both univariate (P = 0.020) and multivariate (P = 0.012) analysis. Survivin expression levels were neither associated with patient clinicopathologic characteristics nor with survival. However, expression of survivin in the nucleus was preferentially detected in stage I and II than in stage III and IV (P = 0.007) in the overall series of NSCLC samples. Taken together, our results suggest that aurora B may represent a valid target in NSCLC. [Mol Cancer Ther 2006;5(11):2905 -13]

show abstract

Section: Discussionmentioning

confidence: 55%

Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients

Vischioni

Oudejans²,

Vos³

et al. 2006

Molecular Cancer Therapeutics

119

View full text Add to dashboard Cite

show abstract

“…Clinically, high levels of XIAP or survivin have been associated with decreased overall survival, increased recurrence and resistance to radiotherapy (Holcik et al, 2000;Rodel et al, 2003). Several reports demonstrated an association between high levels of survivin and poor survival in patients with resected non-small-cell lung cancer (Monzo et al, 1999;Ikehara et al, 2002). However, similar association has not been consistently found for XIAP (Ferreira et al, 2001;Hofmann et al, 2002).…”

Section: Introductionmentioning

confidence: 75%

XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer

et al. 2004

View full text Add to dashboard Cite

Survivin and XIAP are members of inhibitors of apoptosis (IAPs) family. They are upregulated in various malignancies. Inactivation of these molecules has resulted in chemosensitization. The purpose of this study was to determine whether inhibition of survivin, XIAP, or both enhances radiotherapy in a lung cancer model. Transient transfection of H460 cells with antisense oligonucleotides (ASOs) against either molecule has specifically reduced their expression, by Western analysis. Results from 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide and clonogenic assays suggest that inhibition of survivin or XIAP greatly decreased cell survival following irradiation. A significantly increased number of apoptotic cells were detected when H460 cells were treated with either antisurvivin, anti-XIAP or both ASOs (P ¼ 0.03, 0.0003 and 0.01, respectively) plus irradiation. H460 xenografts that were treated with ASOs plus radiotherapy demonstrated growth delay beyond 15 days. Growth delay in the groups of combined treatment was greater than that in other groups. However, treatment with ASOs alone did not affect tumor growth delay in mice, but decreased the survival of H460 cells in culture. Antisense treatment did not cause any mortality or weight loss during the 32 days of study. These data suggest that inhibition of survivin or XIAP radiosensitizes H460 lung cancer cells by upregulating apoptosis and downregulating cell survival. Combination of radiotherapy and inhibition of survivin and XIAP through the antisense approach results in improved tumor control by radiotherapy in a mouse model of lung cancer.

show abstract

“…Several studies have shown that survivin is a prognostic indicator for poor survival in several malignancies (Adida et al, 2000;Chakravarti et al, 2002;Kennedy et al, 2003;Trieb et al, 2003). Survivin protein level examined by immunostaining was associated with vascular invasion and poor survival (Ikehara et al, 2002). However, the predictive value of survivin mRNA examined by RT -PCR is contradictory between two independent studies (Monzo et al, 1999, Falleni et al, 2003.…”

mentioning

confidence: 66%

“…Both mRNA and protein levels of survivin were shown to predict unfavourable survival in patients with resected NSCLC (Monzo et al, 1999;Ikehara et al, 2002). Since survivin has dual function in apoptosis and mitosis depending upon its cellular localisation, the predictive value of nuclear vs cytoplasmic staining of survivin has been investigated in a number of malignancies.…”

Section: Discussionmentioning

confidence: 99%

Nuclear survivin as a biomarker for non-small-cell lung cancer

et al. 2004

View full text Add to dashboard Cite

Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung

Cited by 39 publications

References 0 publications

Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients

Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients

XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer

Nuclear survivin as a biomarker for non-small-cell lung cancer

Contact Info

Product

Resources

About